The ID-Cap System is FDA cleared as an ingestible event marker and has the unique capability to guide digital and non-digital therapeutic interventions.
Fremont, CA: Digital health company etectRx has entered into an agreement with Pear Therapeutics to develop up to two product candidates in the Central Nervous System (CNS) space combining Prescription Digital Therapeutics (PDTs) and adherence sensors. The collaboration is the first of its kind to explore the use of digital pill solutions with PDTs.
"This collaboration between etectRx and Pear Therapeutics comes at a critical time for the mental health field, an area that is in dire need of immediate solutions," said Valerie Sullivan, president, and CEO of etectRx. "Our goal for this collaboration is to bring concrete solutions to those who need it."
etectRx's FDA cleared ID-Cap System, a digital pill system that is accurate, flexible, and elegant, enhances medication adherence, and improves patient outcomes. The ID-Cap System is FDA cleared as an ingestible event marker and has the unique capability to guide digital and non-digital therapeutic interventions.
"We see a significant opportunity for PDTs that involve digital pill technologies, like the ID-Cap System," said Corey McCann, M.D., Ph.D., president, and CEO of Pear Therapeutics. "Optimized medication dosing presents a treatment lever for PDTs and creates opportunity for a whole range of drug/software combination products.
